Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management

Commentary
Podcast

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by AstraZeneca, we had the pleasure of speaking with Jessica S. Donington, MD, MSCR, and Brendon M. Stiles, MD, about surgical perspectives on key lung cancer treatment developments.

Dr Donington is a professor of surgery and chief of the Section of Thoracic Surgery in the Department of Surgery at the University of Chicago Comprehensive Cancer Center in Illinois. Dr Stiles is chief of Thoracic Surgery and Surgical Oncology, as well as the associate director of Surgical Oncology at Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, where he is also a professor in the Department of Cardiothoracic & Vascular Surgery, a professor in the Department of Oncology (Medical Oncology), and a professor in the Department of Medicine (Oncology & Hematology).

In part 2 of our exclusive 2-part interview, Drs Donington and Stiles discussed the implications of perioperative immunotherapy trials on early-stage disease management, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management according to the American Association of Thoracic Surgery, Society of Thoracic Surgeons, and National Comprehensive Cancer Network.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

Related Videos
Thomas F. Gajewski, MD, PhD
Nan Chen, MD
Akriti Jain, MD